Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare type I retinopathy of prematurity (ROP) with aggressive posterior retinopathy of prematurity (AP-ROP) regarding risk factors, complications and treatment outcomes.

Methods

A prospective cohort approach was applied on premature newborns diagnosed as type I ROP and AP-ROP. An intravitreal injection of bevacizumab (Avastin®) was given to each patient. Demographic features such as gestational age, birth weight, age at the initial injection, involved eye, treatment response, relapses and need to extra interventions were compared.

Results

Seventy-seven patients underwent an initial intravitreal injection of bevacizumab (IVB), and 108 eyes were type I ROP and 30 eyes were AP-ROP. There was no significant difference in birth weight and gestational age between two groups. ROP relapsed in eight eyes of four patients with AP-ROP (26.6%), of which six eyes of three patients received re-injection of bevacizumab, and two eyes of one patient underwent a laser treatment. Recurrence occurred in two eyes of one patient with type I ROP (1.8%), which were treated by laser.

Conclusion

Bilateral eye involvement, relapse and retreatment (IVB, laser and surgical intervention) are more frequent in AP-ROP than type I ROP even when treated with intravitreal bevacizumab injection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML et al (2013) Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 33(2):329–338

    Article  CAS  Google Scholar 

  2. Terry TL (1944) Retrolental fibroplasia in the premature infant: V. Further studies on fibroplastic overgrowth of the persistent tunica vasculosa lentis. Trans Am Ophthalmol Soc. 42:383–396

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Mutlu FM, Sarici SU (2013) Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 6(2):228–236

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol (Chicago, Ill 1960) 121(12):1684–1694

    Article  Google Scholar 

  5. Soejima N, Takagi I, Takashima Y (1976) Clinical studies on retinopathy of prematurity, severe and rapidly progressive type. Folia Ophthalmol Jpn 27(1):155–161

    Google Scholar 

  6. Aaberg T, Ben-Sira I, Charles S, Clarkson J, Cohen BZ, Flynn J, Foos R, Garner A, Hirose T, Koerner F, Machemer R (1987) An international classification of retinopathy of prematurity. II. The classification of retinal detachment. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. Arch Ophthalmol (Chicago, Ill 1960) 105(7):906–912

    Article  Google Scholar 

  7. International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123(7):991–999. https://doi.org/10.1001/archopht.123.7.991

    Article  Google Scholar 

  8. Gilbert C (2008) Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 84(2):77–82

    Article  Google Scholar 

  9. Feng J, Qian J, Jiang Y et al (2017) Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China. Ophthalmology 124(3):408–409

    Article  Google Scholar 

  10. Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 35(4):675–680

    Article  CAS  Google Scholar 

  11. Erol MK, Coban DT, Sari ES et al (2015) Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol 78(6):340–343

    Article  Google Scholar 

  12. Khodabande A, Niyousha MR, Roohipoor R (2016) A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity. J AAPOS 20:490–492

    Article  Google Scholar 

  13. Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ (2005) Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 115(4):990–996

    Article  Google Scholar 

  14. Woo SJ, Park KH, Ahn J et al (2011) A co-twin study of the relative effect of birth weight and gestational age on retinopathy of prematurity. Eye (London) 25(11):1478–1483

    Article  CAS  Google Scholar 

  15. Dhaliwal CA, Fleck BW, Wright E, Graham C, McIntosh N (2009) Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed 94(3):F193–F195

    Article  CAS  Google Scholar 

  16. Sanghi G, Dogra MR, Das P, Vinekar A, Gupta A, Dutta S (2009) Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment. Retina 29:1335–1339

    Article  Google Scholar 

  17. Nicoară SD, Ştefănuţ AC, Nascutzy C, Zaharie GC, Toader LE, Drugan TC (2016) Regression rates following the treatment of aggressive posterior retinopathy of prematurity with bevacizumab versus laser: 8-year retrospective analysis. Med Sci Monit 22:1192–1209

    Article  Google Scholar 

  18. Li Xiu-Juan, Yang Xiao-Peng, Sun Shuang, Lyu Xiao-Bei, Jia Heng (2016) Intravitreal ranibizumab for aggressive posterior retinopathy of prematurity. Chin Med J (Engl) 129(23):2879–2881

    Article  Google Scholar 

  19. Chen S-N, Lian I, Hwang Y-C et al (2015) Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina 35(4):667–674

    Article  CAS  Google Scholar 

  20. Castellanos MAM, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H (2013) Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 97(7):816–819

    Article  Google Scholar 

  21. Sukgen EA, Koçluk Y (2017) The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol 80(1):30–34

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Retina and Vitreous Service, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

    Amir Eftekhari Milani, Mohammadreza Mousavi Mirkala, Arash Taheri & Mohamad Reza Niyousha

  2. Retina and Vitreous Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran

    Narges Hassanpoor

  3. Tabriz University of Medical Sciences, Tabriz, Iran

    Ali Golizade

  4. Eye Research Center, Nikookari Eye Hospital, Abbasi Street, Tabriz, 5154645395, Iran

    Mohamad Reza Niyousha

Authors
  1. Amir Eftekhari Milani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Narges Hassanpoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammadreza Mousavi Mirkala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arash Taheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ali Golizade
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohamad Reza Niyousha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamad Reza Niyousha.

Ethics declarations

Conflict of interest

There is no grant and no conflict of interest for all authors.

Ethical approval

This study was conducted based on principles of the Declaration of Helsinki. The study protocol was supervised and approved by the Ethical Committee of Tabriz University of Medical Sciences.

Inform consent

The written inform consent was received from all the participants’ legal parents.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eftekhari Milani, A., Hassanpoor, N., Mousavi Mirkala, M. et al. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity. Int Ophthalmol 40, 477–482 (2020). https://doi.org/10.1007/s10792-019-01208-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-019-01208-3

Keywords

Search

Navigation